The estimated Net Worth of Robert I Taber is at least $7.87 Тысяча dollars as of 28 January 2013. Robert Taber owns over 5,000 units of Palatin Technologies stock worth over $7,865 and over the last 21 years Robert sold PTN stock worth over $0.
Robert has made over 1 trades of the Palatin Technologies stock since 2013, according to the Form 4 filled with the SEC. Most recently Robert bought 5,000 units of PTN stock worth $2,950 on 28 January 2013.
The largest trade Robert's ever made was buying 5,000 units of Palatin Technologies stock on 28 January 2013 worth over $2,950. On average, Robert trades about 385 units every 0 days since 2003. As of 28 January 2013 Robert still owns at least 5,500 units of Palatin Technologies stock.
You can see the complete history of Robert Taber stock trades at the bottom of the page.
Robert's mailing address filed with the SEC is , , , , .
Over the last 22 years, insiders at Palatin Technologies have traded over $3,929,269 worth of Palatin Technologies stock and bought 390,692 units worth $374,235 . The most active insiders traders include Austin W & Greenhouse David..., Partners L P/Ilbiotechnolog... и Carl Spana. On average, Palatin Technologies executives and independent directors trade stock every 76 days with the average trade being worth of $128,497. The most recent stock trade was executed by Stephen T Wills on 1 August 2024, trading 4,999 units of PTN stock currently worth $8,298.
palatin technologies, inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the united states. the company's lead product is vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. it is also developing oral pl8177, a selective melanocortin receptor (mcr) 1 agonist peptide that has completed phase i clinical trial for the treatment of inflammatory bowel diseases; and systemic pl8177, which has completed phase i clinical trial for treating non-infectious uveitis and covid-19. in addition, the company engages in the development of pl9643, a peptide melanocortin agonist active at multiple mcrs, including mc1r and mc5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. further, it is developing pl3994, a natriuretic peptide receptor (npr)-a agonist and sy
Palatin Technologies executives and other stock owners filed with the SEC include: